Piclidenoson

Overview

CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

Indication

Investigated for use/treatment in cancer/tumors (unspecified), eye disorders/infections, psoriasis and psoriatic disorders, and rheumatoid arthritis. Can-Fite BioPharma has reported that by targeting the adenosine A3-receptor, CF101 may also be used to treat Crohn's disease, a serious gastrointestinal disorder.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy	2024/10/16	NCT06643260	Phase 3	Not yet recruiting	Can-Fite BioPharma
Piclidenoson for Treatment of COVID-19	2020/04/03	NCT04333472	Phase 2	Completed	Can-Fite BioPharma
Safety &Efficacy of CF101 to Subjects With Uveitis	2013/07/23	NCT01905124	Phase 2	Withdrawn	Can-Fite BioPharma
Trial of CF101 to Treat Patients With Psoriasis	2010/12/23	NCT01265667	Phase 2	Completed	Can-Fite BioPharma
Trial of CF101 to Treat Patients With Dry Eye Disease	2010/11/05	NCT01235234	Phase 3	Completed	Can-Fite BioPharma
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis	2009/12/17	NCT01034306	Phase 2	Completed	Can-Fite BioPharma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure	2009/12/16	NCT01033422	Phase 2	Completed	Can-Fite BioPharma
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee	2009/02/05	NCT00837291	Phase 2	Withdrawn	Can-Fite BioPharma
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients	2007/11/12	NCT00556894	Phase 2	Completed	Can-Fite BioPharma
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca	2006/07/07	NCT00349466	Phase 2	Completed	Can-Fite BioPharma

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Can-Fite BioPharma Secures $3 Million in Funding to Advance Clinical Trials for Oncology and Inflammatory Disease Treatments

3 months ago

• Can-Fite BioPharma has secured $3 million through a registered direct offering of 2.5 million American Depositary Shares priced at $1.20 per ADS, with the transaction expected to close by April 15, 2025. • The biotech company plans to allocate the proceeds toward advancing its pipeline of small-molecule drugs, including Piclidenoson for psoriasis, Namodenoson for liver cancer and MASH, and CF602 for erectile dysfunction. • Namodenoson has received Orphan Drug Designation in both the U.S. and Europe, as well as Fast Track Designation from the FDA as a second-line treatment for hepatocellular carcinoma.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access